If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Cyramza Summary of Product Characteristics (SmPC)
Cyramza® (ramucirumab): Pregnancy and Lactation
Based on its mechanism of action, ramucirumab may cause foetal harm. It is recommended to avoid pregnancy and discontinue nursing while taking ramucirumab.
animal studies have been specifically conducted to evaluate the
effect of ramucirumab on female reproduction and fetal development,
and there are no studies in pregnant women1
on ramucirumab’s mechanism of action, it is likely that
ramucirumab will inhibit angiogenesis and may potentially result in
adverse effects during pregnancy and postnatal development.1
the use of ramucirumab in pregnant women, and only use if the
potential benefit to the mother justifies the potential risk to the
fetus. Counsel women of childbearing potential or women who become
pregnant during treatment of the potential risks of ramucirumab to
the fetus and for maintaining pregnancy.1
on the half-life of ramucirumab, advise females of reproductive
potential to avoid getting pregnant while receiving ramucirumab and
for at least 3 months after the last dose of ramucirumab.1
is not known whether ramucirumab is secreted in human milk. Human
immunoglobulin G is excreted in human milk and due to potential risks
to the nursing infant, it is recommended to discontinue nursing or
Cyramza [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.